DOJ Signs Schedule III Order: 280E Tax Relief Starts Now for State Operators

Acting Attorney General Todd Blanche signed an order on April 23, 2026 moving state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act — ending decades of federal classification that treated the plant as equivalent to heroin and immediately lifting the punitive 280E tax regime for qualifying operators. The DOJ Schedule III order takes effect now for two defined categories: FDA-approved drug products containing marijuana, and marijuana products regulated under a qualifying state medical cannabis license.

For the nearly 40 states running medical cannabis programs, the practical impact lands first on the tax line. As of April 22, 2026, state-licensed medical cannabis is no longer subject to Section 280E of the Internal Revenue Code. That is an overnight shift in the unit economics of medical cannabis that operators have been asking for since the Obama-era rescheduling petitions.

What the Order Actually Does

The April 23 order is narrower than full federal legalization, and narrower than the broader rescheduling petition the Justice Department first floated in 2024. It does two specific things.

First, it immediately reclassifies state-licensed medical marijuana and FDA-approved marijuana drug products to Schedule III, a category that includes ketamine, anabolic steroids, and Tylenol with codeine. Schedule III is still a controlled substance, and federal handling rules still apply. But Schedule III removes the most punitive treatment under the tax code and eases the DEA's historical barriers to research.

Second, the order directs the DEA to hold an expedited administrative hearing — currently scheduled to begin June 29, 2026 — to consider rescheduling all cannabis from Schedule I to Schedule III. That broader proceeding would cover adult-use state markets as well as medical programs, though no decision is guaranteed from the hearing itself.

The order does not legalize marijuana at the federal level, does not affect current federal incarceration, and does not preempt state law. It also explicitly does not authorize interstate commerce in cannabis.

The 280E Math Changes Overnight

Section 280E of the Internal Revenue Code bars deductions for ordinary business expenses — rent, payroll, marketing, utilities — for any business trafficking in Schedule I or Schedule II controlled substances. Cannabis has been stuck there since 1982, when Congress wrote 280E in response to a cocaine dealer deducting his scale and pager.

Under 280E, cannabis operators could deduct cost of goods sold but virtually nothing else. The result has been effective federal tax rates for some operators approaching or exceeding 75% of net income, even when the business was losing cash. Publicly traded multi-state operators have disclosed 280E tax liabilities in the hundreds of millions of dollars.

With state-licensed medical cannabis moved to Schedule III, 280E no longer applies to qualifying sales. A dispensary that spent 2025 paying federal tax on rent and budtender wages can start claiming those deductions on 2026 activity. The order also encourages the Secretary of the Treasury to consider retroactive 280E relief for past tax years during which operators held state medical licenses — potentially unlocking hundreds of millions in refund claims. The order is careful to note it is not a final determination of federal tax liability, and operators are being advised to coordinate with tax counsel before filing amended returns.

For publicly traded cannabis companies, the 280E reversal has been the single most consequential tax change in the industry's history. For smaller state operators, it is often the difference between solvency and closure.

Who Qualifies and Who Doesn't

The order draws a bright line between medical and adult-use cannabis. State-licensed medical marijuana qualifies for Schedule III immediately. Recreational cannabis — even when sold by the same multi-state operator through the same retail footprint — remains Schedule I until the broader DEA proceeding concludes.

That creates a messy accounting problem for vertically integrated companies that sell into both medical and adult-use markets. Operators will need to segregate medical-licensed inventory, sales, and expenses from adult-use activity to calculate which portion qualifies for Schedule III treatment. Industry tax advisors are already pushing standardized methodologies for allocating shared costs — a dispensary's rent, for example, when the same storefront serves both patient and recreational customers.

Hemp products regulated separately under the 2018 Farm Bill are not directly affected. CBD and hemp-derived cannabinoid products remain governed by their existing federal framework, though some of the hemp-derived intoxicating cannabinoid categories that have been in regulatory limbo may see indirect effects from the broader DEA proceeding.

Industry Stakeholder Reactions

The order generated rapid public reaction across the industry. Publicly traded operators issued supportive statements within hours, with executives at Trulieve, Tilray, Canopy Growth, and Curaleaf framing the order as validation of medical cannabis's therapeutic legitimacy and a long-overdue correction to a tax regime that singled out a single legal-under-state-law industry.

Equity markets moved first. On April 22, 2026 — the day before the signed order — reports of the pending action sent cannabis stocks sharply higher. Canopy Growth (CGC) jumped more than 19% on the session, Tilray (TLRY) finished up 14.2%, Curaleaf (CURLF) surged 26.3%, and the AdvisorShares Pure US Cannabis ETF (MSOS) climbed 19.4%.

Opposition was equally swift. Smart Approaches to Marijuana, the legalization-opposition advocacy group founded by Kevin Sabet, announced it would take immediate legal action to challenge the order. The group's likely legal argument centers on procedural questions — whether the DOJ had authority to act via order rather than through the standard APA rulemaking and DEA scheduling review process, and whether the narrower Schedule III carve-out for state-licensed medical cannabis complies with the underlying statutory scheme.

What Happens at the June 29 DEA Hearing

The expedited DEA hearing scheduled to begin June 29, 2026 is the larger stake. The administrative proceeding will consider whether all cannabis — including adult-use state markets — should be moved to Schedule III. That hearing will take evidence, hear from stakeholders, and produce a recommendation the Attorney General would act on.

A Schedule III outcome for all cannabis would extend 280E relief to adult-use operators, significantly expand research access, and mark the most consequential federal cannabis policy shift since the Controlled Substances Act was enacted in 1970. It would still not legalize cannabis federally or clear a pathway to interstate commerce, but it would bring the bulk of the licensed US cannabis industry under a substantially lighter federal regulatory touch.

Industry attorneys are already modeling scenarios in which the hearing produces a phased approach — Schedule III for adult-use on a longer timeline, with additional guardrails around marketing and youth access. Others expect the hearing to narrow the order's scope under pressure from enforcement and public health stakeholders. The SAM lawsuit could also slow the June timeline if a court grants interim relief.

What Operators Should Do Right Now

For state-licensed medical cannabis businesses, the immediate priorities are tax and compliance housekeeping. That means documenting the state medical licenses that qualify for Schedule III treatment, beginning to segregate medical from adult-use cost pools for the 2026 tax year, and evaluating whether to file protective refund claims for open prior tax years pending Treasury guidance on retroactive relief.

Operators should also expect new federal reporting and security requirements to accompany Schedule III status. Schedule III substances are still controlled, and pharmaceutical-grade record-keeping, secure storage, and prescription handling rules apply to FDA-approved products. State medical marijuana programs will continue to run under their existing state licensing frameworks, but federal enforcement priorities may shift.

Key Takeaways

• The DOJ signed an order on April 23, 2026 immediately reclassifying state-licensed medical marijuana and FDA-approved cannabis products to Schedule III.
• Section 280E no longer applies to qualifying state medical cannabis sales as of April 22, 2026.
• Retroactive 280E relief is possible but not guaranteed — Treasury must still issue guidance.
• An expedited DEA hearing beginning June 29, 2026 will consider rescheduling all cannabis to Schedule III.
• Adult-use and interstate commerce remain unaffected by the current order.
• Smart Approaches to Marijuana has announced legal challenges.

Explore cannabis news, find dispensaries, and join the community at Budpedia.